These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 32652979)

  • 1. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
    Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
    J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
    [No Abstract]   [Full Text] [Related]  

  • 3. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
    Dempsey TM; Payne S; Sangaralingham L; Yao X; Shah ND; Limper AH
    Ann Am Thorac Soc; 2021 Jul; 18(7):1121-1128. PubMed ID: 33465323
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; de Andrade J
    J Med Econ; 2022; 25(1):532-540. PubMed ID: 35321616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States.
    Qiu Y; Zhu J; Chopra P; Elpers B; Dieyi C; Byrne C; Tang J; Wang Y; Govindaraj K; Fischer A
    Ther Adv Respir Dis; 2024; 18():17534666241280704. PubMed ID: 39418137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
    Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
    Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.
    Dempsey TM; Thao V; Moriarty JP; Borah BJ; Limper AH
    BMC Pulm Med; 2022 Jan; 22(1):18. PubMed ID: 35000589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.
    Kelly BT; Thao V; Dempsey TM; Sangaralingham LR; Payne SR; Teague TT; Moua T; Shah ND; Limper AH
    BMC Pulm Med; 2021 Jul; 21(1):239. PubMed ID: 34273943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
    Dempsey TM; Sangaralingham LR; Yao X; Sanghavi D; Shah ND; Limper AH
    Am J Respir Crit Care Med; 2019 Jul; 200(2):168-174. PubMed ID: 31150266
    [No Abstract]   [Full Text] [Related]  

  • 19. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
    Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
    Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
    Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
    Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.